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peritoneal dialysis.
Background. Dyslipidemia is often observed in patients with
end-stage renal disease (ESRD) and is associated with car-
diovascular diseases. Peritoneal dialysis treatment may further
deteriorate the lipoprotein abnormalities, suggesting that peri-
toneal dialysis alters lipid metabolism.
Methods. To study the mechanisms involved in these abnor-
malities in peritoneal dialysis, we measured insulin sensitivity,
free fatty acids release, de novo lipogenesis (DNL), very low-
density lipoprotein (VLDL) apoB100 kinetics and cholesterol
synthesis in vivo in ESRD (N = 6), peritoneal dialysis patients
(N = 5), and controls (N = 7) using stable isotopes.
Results. Insulin sensitivity, as assessed by an euglycemic hy-
perinsulinemic clamp, tended to be lower in ESRD and peri-
toneal dialysis compared to controls [P = 0.08 by analysis
of variance (ANOVA)]. Free fatty acid release during the
euglycemic hyperinsulinemic clamp tended to be higher in
ESRD and peritoneal dialysis compared to controls (P = 0.08
by ANOVA), while DNL and fractional cholesterol synthe-
sis were normal. VLDL-1 apoB100 (P < 0.05) and VLDL-2
apoB100 pool sizes (P < 0.05) were significantly higher in peri-
toneal dialysis patients compared to controls. The increased
VLDL-1 apoB100 pool size was explained by increased VLDL-
1 apoB100 synthesis (P < 0.05) in combination with reduced
VLDL-1 apoB100 catabolism (P < 0.01), while the increased
VLDL-2 apoB100 pool was explained by reduced catabolism
(P < 0.01).
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Conclusion. Both VLDL-1 apoB100 and VLDL-2 apoB100
pool sizes are increased in peritoneal dialysis patients, due to dis-
turbances both in synthesis and catabolism. VLDL-1 apoB100
production is, at least partially, explained by increased free fatty
acid availability secondary to peripheral insulin resistance, thus
identifying insulin resistance as potential therapeutic target in
peritoneal dialysis patients.
In renal failure, multiple risk factors are present that
contribute to cardiovascular diseases [1, 2]. One of these
risk factors, dyslipidemia, is already observed early in the
course of renal disease [3] and has been forwarded as an
independent risk factor for development of cardiovascu-
lar disease in end-stage renal disease (ESRD) and renal
replacement therapy [4, 5]. Hemodialysis as well as peri-
toneal dialysis can both provide adequate relief of uremic
symptoms, but the dialysis techniques appear to have dif-
ferential effects on uremic dyslipidemia. Plasma trigly-
ceride levels, plasma cholesterol and apoB100 levels are
higher in peritoneal dialysis compared to hemodialysis,
indicating that differences in lipoprotein metabolism are
partly attributable to peritoneal dialysis treatment rather
than uremia per se [6, 7]. The increase in apoB100 in peri-
toneal dialysis patients is most markedly in the very low-
density lipoprotein (VLDL) fraction an to a minor extent
in intermediate-density lipoprotein (IDL) and low-
density lipoprotein (LDL) [8], while long-term treatment
with peritoneal dialysis may further deteriorate some of
these lipoprotein abnormalities [9, 10].
Several groups have studied the metabolism of dyslipi-
demia in ESRD before and after dialysis treatment and
there has been debate about the mechanisms responsi-
ble for the dyslipidemia. Some groups reported impaired
removal of triglyceride-rich lipoproteins [11–13], while
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Fig. 1. Hypothetical model for hypertriglyceridemia in end-stage re-
nal disease (ESRD). One of the key players is insulin. Reduced insulin
sensitivity present in peripheral tissues in ESRD (1), contributes to
increased free fatty acid (FFA) release (2). These free fatty acids are
subsequently oxidized or esterified, where after, if not stored, free fatty
acids are directed to very low-density lipoprotein (VLDL) apolipopro-
tein B (apoB100) synthesis (3). As peritoneal dialysis treatment is ini-
tiated, aggravation of hypertriglyceridemia occurs, that could be the
result of stimulation of de novo lipogenesis (DNL) due to glucose load-
ing (4) or substantial protein loss (5). High plasma concentrations of
triglyceride (TG)-rich lipoproteins leads to increased release of free
fatty acids and generation of remnants as a result of lipolysis by lipopro-
tein lipase (LPL). These free fatty acids are subjected to the liver,
thereby setting up a vicious cycle and further driving VLDL production.
other studies suggest overproduction of lipoproteins, in
particular VLDL [13, 14] as well.
In Figure 1, we propose a model for dyslipidemia fo-
cused on hypertriglyceridemia in ESRD that takes into
account different metabolic pathways as proposed re-
cently in more detail [15]. One of the key players in this
model is insulin resistance [Fig. 1 (1)] [16]. Reduced in-
sulin sensitivity is present in renal failure [17, 18]. As a
consequence of peripheral insulin resistance, increased
free fatty acids [Fig. 1 (2)] are transported to the liver,
where they are subjected to oxidation or re-esterification.
Subsequently, re-esterified fatty acids are either stored as
cytosolic triglycerides or secreted in VLDL apolipopro-
tein B100 (apoB100) containing particles [Fig. 1 (3)] [19].
As VLDL apoB100 is a substrate driven process, such in-
creased free fatty acid delivery to the liver may result in
enhanced VLDL release. Dialysis treatment may aggra-
vate these processes. In particular, in peritoneal dialysis
in which substrate availability for VLDL secretion may
also be enhanced due to de novo lipogenesis (DNL) asso-
ciated with the repetitive glucose loading by the dialysis
fluid on a background of insulin resistance [Fig. 1 (4)] [9,
20]. In addition, peritoneal dialysis is associated with sub-
stantial protein loss in the dialysate [21–23], which may
in an analogous way as reported in the nephrotic syn-
drome further aggravate lipoprotein abnormalities [Fig. 1
(5)] [24]. High plasma concentrations of triglyceride-
rich lipoproteins (VLDL and chylomicrons) [25] subse-
quently lead to an increase in the release of free fatty
acids and generation of remnants thereby initiating a vi-
cious cycle and further driving VLDL production.
In this report, we tested this model in patients with
ESRD and patients on peritoneal dialysis treatment, us-
ing endogenous labeling with [1-13C]-valine for apoB100,
[1-13C]-acetate for DNL and cholesterol synthesis and
[2,2-2H2]-palmitate to determine free fatty acid release.
METHODS
Subjects
Six patients with ESRD (three males and three fe-
males), five peritoneal dialysis patients (two males and
three females), and seven controls (five males and two
females) participated in the study. Two patients in the
ESRD group had reflux nephropathy, one patient had
interstitial nephritis, one patient had IgA nephropathy,
one patient had chronic pyelonephritis and the cause of
renal disease in one patient was unknown. The patients
in the peritoneal dialysis group had glomerulonephritis,
interstitial nephritis, reflux nephropathy, and in two pa-
tients the cause of renal failure was unknown. Patients on
peritoneal dialysis treatment included those on continu-
ous ambulatory peritoneal dialysis (CAPD) or CAPD in
combination with automated peritoneal dialysis (APD).
Patients underwent dialysis for at least 9 months. Two pa-
tients from the ESRD group (patients 1 and 2) dropped
out (one kidney transplantation and one death, respec-
tively). The other patients had not started peritoneal
dialysis yet. Patients with type 2 diabetes, familial hy-
percholesterolemia (FH), familial combined hyperlipi-
demia (FCH) and/or underlying cardiovascular disease
and patients with volume overload were excluded from
the study. The clinical data of the patients and controls are
shown in Table 1. Patients and controls were matched for
age, weight, body mass index (BMI), and body surface
area (BSA). The calculated creatinine clearance, using
the Cockcroft-Gault formula, was significantly decreased
in ESRD compared to controls (9 ± 1 mL/min/1.73 m2
versus 92 ± 10 mL/min/1.73 m2, P < 0.001). Mean Kt/V
value in the peritoneal dialysis group, where V was esti-
mated by the formula of Watson and Watson, was 2.01 ±
0.16 (range 1.70 to 2.55). Lipid-lowering medication was
stopped at least 4 weeks before participation in the
study and specific medication other than vitamins, ery-
thropoietin, iron supplementation, sodium bicarbonate,
and phosphate binder supplementation are presented in
Table 1. Patients 4 and 9 smoked cigarettes. Before iso-
tope infusion, the patients recorded their food intake for
3 days and collected 24-hour urine for 3 consecutive days.
Additionally, the peritoneal dialysis group also collected
24-hour dialysis fluid for 3 days.
Control subjects also recorded their food intake for 3
days and collected one 24-hour urine sample. All patients
and volunteers agreed to participate after signing an
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Table 1. Clinical data of the patients and control subjects
Creatinine
clearance
mL/min/
Renal disease Age years Gender Weight kg BMI kg/m2 BSA m2 1.73 m2 Kt/V Medication
ESRD patients (N = 6)
1 Chronic pyelonephritis 59 M 82.6 27.9 2.0 8 — 1
2 Reflux nephropathy 49 M 72.6 23.7 1.9 7 — 1
3 Interstitial nephritis 51 M 85.7 25.9 2.1 11 — —
4 Reflux nephropathy 29 F 71.1 26.1 1.8 14 — 1,2
5 IgA nephropathy 19 F 83.0 31.2 1.9 9 — 1
6 Unknown 56 F 74.4 25.7 1.9 9 — —
Mean ± SEM 44 ± 7NS 3 M/3 F 78.3 ± 2.5NS 26.8 ± 0.9NS 1.9 ± 0.0NS 9 ± 1a —
Peritoneal dialysis patients (N = 5)
7 Glomerulonephritis 49 M 87.1 26.0 2.1 — 1.70 2
8 Unknown 54 M 78.3 26.2 1.9 — 2.55 1
9 Interstitial nephritis 54 F 69.3 24.0 1.8 — 1.90 1
10 Unknown 45 F 58.8 20.8 1.7 — 1.70 1
11 Reflux nephropathy 53 F 68.1 28.0 1.7 — 2.19 2
Mean ± SEM 51 ± 2NS 2 M/3 F 72.3 ± 4.8NS 25.0 ± 1.2NS 1.8 ± 0.0NS — 2.01 ± 0.16
Control subjects (N = 7)
Mean ± SEM 48 ± 3 5M/2F 77.4 ± 5.1 24.3 ± 0.9 1.9 ± 0.1 92 ± 10 — —
Abbreviations are: ESRD, end-stage renal disease; BMI, body mass index; BSA, body surface area; 1, angiotensin-converting enzyme (ACE) inhibitor; 2, b-blocker;
NS, not significant.
aP < 0.001, compared to controls.
informed consent form, in accordance with the Helsinki
Declaration of Human Rights. The Institutional Eth-
ical Committee for studies in humans approved this
study.
Study design
The subjects were studied on two occasions. In the first
study, apoB100 kinetics, DNL and whole-body choles-
terol synthesis were studied. In the second study, which
was performed within 2 to 3 weeks after the first infu-
sion, insulin sensitivity and free fatty acid release into
blood were studied. Infusion protocols on day 1 and day
2 are depicted in Figure 2, respectively.
On day 1, the subjects came to the research unit in the
morning after 10 hours of fasting. Two intravenous can-
nulas were placed (brachial vein) for blood sampling and
infusion of the labeled valine. No food was given during
the tracer infusion and the subjects were only allowed to
drink water. If peritoneal dialysis patients were studied,
the last bag of peritoneal dialysate had been drained for
at least 6 hours prior to the start of tracer infusion. During
the infusion period, no dialysis was performed.
At baseline (t = 0), ESRD patients received a prim-
ing dose of 11.5 lmol/kg L-[1-13C]-valine (isotope mole
fraction > 0.99) (Mass Trace, Woburn, MA, USA) intra-
venously in 2 minutes, followed by a continuous infusion
of 11.5 lmol/kg/hour L-[1-13C]-valine for 10 hours. The
priming dose was 8 lmol/kg for peritoneal dialysis pa-
tients and 15 lmol/kg for control subjects, followed by a
continuous infusion of 8 lmol/kg/hour and 15 lmol/kg/
hour for 10 hours, respectively. During the valine infusion,
the subjects also received every 30 minutes an oral dose of
[1-13C]-valine
0 60 120 180 240 300 360 420 480 540 600 minutes
A
20% glucose
Insulin
[2,2–2H2]–palmitate[2,2–2H2]–palmitate
0 60 120 180 240
Variable
1.2 U/m2/hour
3.0 µmol/kg/hour
minutes
B
Fig. 2. Infusion scheme. (A) Day 1. Subjects received a priming dose
of [1-13C]-valine directly followed by a continuous infusion of the same
amount of tracer for 600 minutes. In addition, subjects received every
half hour 500 mg [1-13C]-acetate, which was administered orally. The
arrows indicate the time-points for collection of blood. (B) Day 2. Sub-
jects received a continuous infusion of [2,2-2H2]-palmitate 70 minutes
before starting the clamp and during the last 70 minutes of the clamp.
Euglycemic hyperinsulinemic clamp was performed at an insulin in-
fusion rate of 1.2 U/m2/hour. The arrows indicate the time-points for
collection of blood for determining of free fatty acid release. Addition-
ally blood samples were taken in order to measure insulin sensitivity.
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500 mg sodium-[1-13C]-acetate (isotope mole fraction >
0.99) (Mass Trace), which was dissolved in water. Blood
samples were taken in heparin-containing and ethylene-
diaminetetraacetic acid (EDTA)-containing tubes from
the contralateral arm at t = 0, 30, 60, 180, 300, 360, 420,
480, 540, and 600 minutes. Samples were kept on ice until
plasma was separated by centrifugation (15 minutes, 3000
rpm, 4◦C) and stored at −80◦C.
Before the second study, the subjects were fasting
again for 10 hours and the conditions in relation to food,
time of dialysis and collection of urine and dialysis fluid
were similar as described above. At baseline (t = 0), the
subjects received a continuous intravenous infusion of
3.0 lmol/kg/hour potassium-[2,2-2H2]-palmitate (isotope
mole fraction > 0.98) (ARC, Amsterdam, The Nether-
lands), which was bound to 20% albumin according to
the protocol described in [26]. After 70 minutes, the
[2,2-2H2]-palmitate infusion was stopped, whereafter in-
sulin sensitivity of the subjects was assessed for 3 hours
by a euglycemic hyperinsulinemic clamp. Human insulin
(Actrapid Human) (Novo Nordisk, Gentofte, Denmark)
was infused intravenously at a rate of 1.2 U/m2/hour for
3 hours (plateau value ∼40 mU/L). Plasma glucose con-
centrations were measured every 5 minutes using arte-
rialized venous blood with a YSI 200 Stat Plus Glucose
analyzer (Salm en Kipp, Breukelen, The Netherlands)
and the 20% glucose solution was infused at a variable
rate to maintain euglycemia at 5.0 mmol/L. During the
last 70 minutes of the clamp, [2,2-2H2]-palmitate was in-
fused again. Before and during the clamp, blood samples
were taken in EDTA and heparin containing tubes from
the contralateral at t = 0, 40, 50, 60, 70, 180, 220, 230, 240,
and 250 minutes. Samples were kept on ice until plasma
was separated by centrifugation (15 minutes, 3000 rpm,
4◦C) and stored at −80◦C.
Preinfusion measurements
Plasma urea, plasma creatinine, plasma glucose, as well
as urea and creatinine in urine and dialysis fluid were
measured with standard laboratory methods on a Vit-
ros 950AT (Johnson & Johnson, Ortho Clinical Diagnos-
tics, Rochester, NY, USA). Total plasma triglycerides and
cholesterol were analyzed by standard enzymatic assays
on a Cobas Mira S (ABX, Montpellier, France), while
free fatty acids were analyzed by a standard enzymatic
assay on a Cobas Fara (ABX). Total plasma apoB and
apoB in the different lipoprotein fractions were measured
using a nephelometric assay (Dade Behring, Marburg,
Germany). Insulin was measured with a competitive ra-
dioimmunoassay using a polyclonal antiinsulin-antibody
(Caris 46), 125I-insulin (IM166) (Amersham, Roosendaal,
The Netherlands) as a tracer and Humuline (YV2632
AMV Lilly, Indianapolis, USA) as a standard. ApoE
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Fig. 3. Multicompartmental model for apolipoprotein B (apoB100)
metabolism. Compartment 1 represents plasma valine into which the
valine tracer was injected. Compartment 2 represents a delay com-
partment and valine in incorporated in very low-density lipoprotein
(VLDL-1) apoB100, VLDL-2 apoB100, intermediate-density lipopro-
tein (IDL) apoB100, and low-density lipoprotein (LDL) apoB100 via
compartments 3, 4, 5, and 6. The k-values represent rate constants.
genotyping was done according to the method described
by Slooter et al [27].
ApoB100 metabolism
The isolation of free amino acids from plasma was per-
formed as described in detail elsewhere [28].
The apoB100 containing lipoproteins (VLDL-1,
VLDL-2, IDL, and LDL) were isolated from 2 mL EDTA
plasma using a discontinuous salt gradient by cumulative
ultracentrifugation as described in [29]. ApoB concen-
trations were determined using a nephelometric assay
(Dade Behring). The detection limit of the apoB assay
was 12 mg/L. In patients who had detectable lipopro-
tein(a) [Lp(a)] concentration in the IDL and LDL frac-
tion, the samples were pretreated with lysine-sepharose
4B to remove the Lp(a) as described in [30]. ApoB100
from the isolated lipoproteins was then precipitated us-
ing isopropanol and isolated as described before [31].
The preparation of N(O,S) methoxycarbonylmethylester
derivatives of apoB100, plasma valine, and mass spectro-
metric measurements were described in detail elsewhere
[31, 32]. ApoB100 production was measured as the rate
of incorporation of 13C-enriched valine into circulating
VLDL-1, VLDL-2, IDL, and LDL apoB100. The best fit
to the actual data points was determined using the SAAM
II software (Simulation Analysis and Modelling, version
1.1.1) (SAAM Institute, Seattle, WA, USA). The com-
partment model is depicted in Figure 3. Compartment
1 represents plasma valine into which the valine tracer
was injected. Compartment 2 represents delay compart-
ment and valine is incorporated into VLDL-1 apoB100,
VLDL-2 apoB100, IDL apoB100, and LDL apoB100 via
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compartments 3, 4, 5, and 6. The absolute synthesis rate
(ASR), which is the amount of protein synthesized per
day, was calculated as the product of the fractional syn-
thesis rate (FSR) and the plasma pool (plasma volume ×
plasma concentration). Plasma volumes in all subjects
were calculated from BSA using the formulas described
by Hurley [33].
DNL
After isolation of the different lipoprotein fractions,
the VLDL-1 and VLDL-2 fraction were used to deter-
mine the contribution of new-formed 13C-palmitate from
[1-13C]-acetate to total palmitate according to the proto-
col described in [34].
In short, in glass tubes, 2 mL methanol/hexane (4:1,
vol/vol) was added to 100 lL VLDL-1 and 100 lL VLDL-
2 fraction. After vortexing, 200 lL acetylchlorid was
added very slowly and incubated for 1 hour at 100◦C,
where after cooling to room temperature, 5 mL 6% potas-
sium carbonate was added. After centrifugation, the hex-
ane fraction containing the palmitate was transferred to
a vial and aspirated under N2. The residue was dissolved
in 50 lL hexane.
For selected ion monitory (SIM) gas chromatography-
mass spectrometry (GC-MS) analysis, 1 lL was delivered
by automatic injection to a HP-5890 gas chromatograph
split injection port (1:20) leading to a 0.2 mm × 25 m
Chrompack CP-sil 19CB (WCOT Fused Silica) capillary
column. The injection port contained a glass wool liner.
The carrier gas was helium at a linear rate of 1 mL/min.
The injection temperature was 240◦C and the detection
temperature was 280◦C. A HP-5989B mass spectrometer
was used as detector. Measurements were done in the
electron impact mode (EI) at 70 eV. The ion source tem-
perature was 250◦C and the quadropole temperature was
150◦C. SIM measurements were done for quantification
of the mass fragments M + 0 (m/z 270), M + 1 (m/z 271),
M + 2 (m/z 272). The peak area for M + 0, M + 1, and M +
2 were integrated, after which the ratios of M + 0/(M +
0. . . M + 2), M + 1/(M + 0. . . M + 2), and M + 2/(M + 0. . .
M + 2) were calculated. Based upon these ratios the FSR
of DNL was determined using mass isotopomer distribu-
tion analysis (MIDA) as described in [35].
Fractional cholesterol synthesis
For cholesterol determination, 50 lL plasma was
deproteinized with 2 mL ethanol/aceton (1:1, vol/vol)
and centrifuged for 10 minutes at 4000 rpm. The
upper layer was dried under nitrogen and deriva-
tized with 50 lL Bis (trimethylsilyl) trifluoroacetamide
(BSTFA)/pyridine (5:1, vol/vol) for 60 minutes at 60◦C.
For SIM-GC-MS analysis, 2 lL of the derivative mix-
ture was delivered by automatic injection to a HP-5890
gas chromatograph as described above. Mass spectromet-
ric data were collected in the selected ion mode at M +
0 (m/z 368), M + 1 (m/z 369), M + 2 (m/z 370), and M
+ 3 (m/z 371). FSR of cholesterol was calculated using
MIDA as described in [36].
Palmitate release
The extraction of plasma lipids and the procedure for
rapid isolation of plasma long chain free fatty acids, in-
cluding palmitate, was done according to the method de-
scribed in [37, 38]. After isolation of the long chain free
fatty acids, the fraction was dried under N2 at room tem-
perature, derivatized and the methylesters were chro-
matographed as described in the section DNL. SIM
measurements were done for quantification of the mass
fragments M + 0 (m/z 270) and M + 2 (m/z 272). A palmi-
tate calibration curve with increased concentrations of
[2,2-2H2]-palmitate (0% to 5%) was used to calculate the
enrichment of the plasma samples.
The palmitate concentration in the infusate was deter-
mined by gas chromatography measurements. Five hun-
dred microliters infusate was added to 50 lL internal
standard (3-phenyl-buteric acid). After adding HCl to a
pH of 1 to 2, the sample was extracted twice with ethyla-
cetate. The ethylacetate fraction was dried and deriva-
tized with 50 lL BSTFA/pyridine (5:1, vol/vol) for 60
minutes at 60◦C. One lL was injected on a Varian 3400
gas chromatograph.
Free fatty acid kinetics were described by a single pool
model [39]. The rate of appearance (Ra) of palmitate is
considered to refer to the total rate of appearance of the
tracee and was calculated using the equation of Steele
[40] for steady-state conditions by dividing palmitate in-
fusion rate by palmitate enrichment at plateau. During
the last 30 minutes of the clamp, where a steady state was
achieved, Ra palmitate was calculated again.
Euglycemic hyperinsulinemic clamp
The glucose infusion rate (GIR) required to maintain
euglycemia (in mmol/min) during the steady state in the
last 30 minutes of the clamp was calculated. Fat free
mass was calculated according to Deurenberg et al [41].
The GIR was expressed per kg fat free mass or per m2
(M value). Insulin sensitivity was calculated as M, ex-
pressed either per fat free mass or m2, divided by the
average plasma insulin concentration, during the last
30 minutes of the clamp.
Statistical analysis
Data are expressed as mean ± SEM. One-way anal-
ysis of variance (ANOVA) assessed the significance of
differences and multiple comparisons were done using
Bonferroni t test. If the tests for normality or equal vari-
ance test failed, a Kruskal-Wallis one-way ANOVA on
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RANKS was performed and multiple comparisons were
done using Dunn’s test. Correlations were performed by
linear regression analysis.
RESULTS
Baseline data
Plasma concentrations of apoB, free fatty acids,
triglycerides, cholesterol, apoB pool size, and apoE geno-
typing are shown in Table 2. Total plasma apoB and total
apoB pool size tended to be greater in dialysis patients
compared to control subjects. Since apoE2 genotype per
se is associated with increased triglyceride concentra-
tions, apoE genotyping of all subjects was determined.
No subjects had apoE2 genotype, while patients 5 and 8
and 2 controls had apoE3/E4 genotype, whereas the other
subjects had apoE3/E3 genotype.
Total plasma triglyceride concentrations tended to be
higher in both patients groups, but were only significant
higher in peritoneal dialysis patients compared to control
subjects (P < 0.05). Plasma cholesterol was not different
between the three groups.
apoB100 kinetics
VLDL-1 apoB100 kinetic is shown in Table 3. VLDL-1
apoB100 pool size was significantly higher in the peri-
toneal dialysis group compared to controls (P < 0.01).
The ASR of VLDL-1 apoB100 was higher in the peri-
toneal dialysis group compared to controls (P < 0.05).
Transfer to VLDL-2 apoB100 (P < 0.05) and total VLDL-
1 apoB100 FCR (P < 0.01) were significantly lower in
the peritoneal dialysis subjects. VLDL-1 apoB100 di-
rect catabolism was similar for both patients groups and
controls.
VLDL-2 apoB100 kinetics are shown in Table 4.
VLDL-2 apoB100 pool size was significantly higher in
the peritoneal dialysis patients compared to controls (P <
0.01). Transfer to IDL apoB100 was significantly lower in
the peritoneal dialysis group (P < 0.01). Total VLDL-2
apoB100 fractional catabolic rate was significant lower
for ESRD (P < 0.05) and peritoneal dialysis patients
(P < 0.01) compared to control subjects. VLDL-2
apoB100 ASR tended to be lower in both patient groups
compared to controls, while no significant difference was
found for VLDL-2 apoB100 direct catabolism.
IDL apoB100 kinetics in all patients and control sub-
jects are shown in Table 5. IDL apoB100 tended to
be higher in both patient groups compared to control
subjects, but were not significantly different. No signif-
icant differences were found for IDL apoB100 synthe-
sis rate, transfer to LDL apoB100, direct IDL apoB100
catabolism, or total IDL apoB100 catabolism in patients
compared to control subjects.
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Table 3. Very low-density lipoprotein (VLDL-1) apolipoprotein B (apoB100) (Sf 60 to 400) metabolism in patients and control subjects
VLDL-1 ASR VLDL-1 ASR VLDL-1 Transfer to Direct Total VLDL-1
apoB100 ApoB100 apoB100 VLDL-2 catabolism FCR
mg mg/day mg/kg/day pools/day pools/day pools/day
ESRD patients (N = 6)
1 105 613 7 2.7 3.1 5.8
2 555 946 13 1.7 0.0 1.7
3 297 652 8 2.2 0.0 2.2
4 128 710 10 5.6 0.0 5.6
5 152 993 12 5.0 1.5 6.5
6 43 915 12 21.3 0.0 21.3
Mean ± SEM 213 ± 76NS 805 ± 68NS 10 ± 1NS 6.4 ± 3.0NS 0.8 ± 0.5NS 7.2 ± 2.9NS
Peritoneal dialysis patients (N = 5)
7 345 1156 13 1.7 1.6 3.3
8 427 1464 19 1.5 1.9 3.4
9 223 879 13 3.9 0.0 3.9
10 686 601 10 0.9 0.0 0.9
11 362 621 9 1.7 0.0 1.7
Mean ± SEM 408 ± 77b 944 ± 165a 13 ± 2a 2.0 ± 0.5a 0.7 ± 0.4NS 2.7 ± 0.6b
Control subjects (N = 7)
Mean ± SEM 68 ± 12 507 ± 58 7 ± 1 7.4 ± 2.1 1.4 ± 1.1 8.8 ± 1.9
Abbreviations are: ESRD, end-stage renal disease; NS, not significant; Sf, svedberg flotation; ASR, absolute synthesis rate; FCR, fractional catabolic rate.
aP < 0.05, compared to controls; bP < 0.01, compared to controls.
Table 4. Very low-density lipoprotein (VLDL-2) apolipoprotein B (apoB100) (Sf 20 to 60) metabolism in patients and control subjects
VLDL-2 ASR VLDL-2 ASR VLDL-2 Direct Total VLDL-2
apoB100 apoB100 apoB100 Transfer to IDL catabolism FCR
mg mg/day mg/kg/day pools/day pools/day pools/day
ESRD patients (N = 6)
1 64 331 4 6.5 3.1 9.6
2 538 213 3 2.2 0.0 2.2
3 463 449 5 2.4 0.0 2.4
4 153 376 5 7.1 0.0 7.1
5 231 412 5 3.5 1.5 5.0
6 89 66 1 11.0 0.0 11.0
Mean ± SEM 256 ± 81NS 307 ± 59NS 4 ± 1NS 5.5 ± 1.4NS 0.8 ± 0.5NS 6.2 ± 1.3a
Peritoneal dialysis patients (N = 5)
7 290 369 4 1.7 1.6 3.3
8 230 299 4 2.2 1.9 4.1
9 256 142 2 4.0 0.0 4.0
10 458 79 1 1.5 0.0 1.5
11 291 247 4 3.0 0.0 3.0
Mean ± SEM 292 ± 35c 227 ± 52NS 3 ± 1NS 2.5 ± 0.5a 0.7 ± 0.4NS 3.2 ± 0.5b
Control subjects (N = 7)
Mean ± SEM 89 ± 10 419 ± 66 5 ± 1 8.5 ± 1.6 1.4 ± 1.1 9.2 ± 1.2
Abbreviations are: ESRD, end-stage renal disease; ASR, absolute synthesis rate; Sf, svedberg flotation; IDL, intermediate-density lipoprotein; NS, not significant;
FCR, fractional catabolic rate.
aP < 0.05; bP < 0.01; cP < 0.001, compared to controls.
LDL apoB100 kinetics in all patients and control sub-
jects are shown in Table 5. LDL apoB100 pool size tended
to be lower in peritoneal dialysis patients. LDL apoB100
synthesis rate, expressed in mg/day tended to be lower in
ESRD, but was significantly lower in peritoneal dialysis
patients compared to control subjects (30 ± 9 mg/day ver-
sus 145 ± 31 mg/day, P < 0.05). No significant difference
was found for total LDL apoB100 fractional catabolic
rate in patients and control subjects. ApoB100 recovery
in all subjects was constant and was 85.2% ± 1.0% (range
83% to 91%).
Insulin sensitivity
Plasma insulin concentrations at the start of the clamp
were higher in ESRD and peritoneal dialysis patients
compared to controls, while plasma insulin concentra-
tions were only significant higher in the ESRD group
than in controls (P < 0.01). During the last 30 minutes
of the clamp, an insulin plateau value of ∼40 mU/L was
achieved in the three groups. Fasting glucose levels were
not significantly different between patients and controls
at the beginning as well as at the end of the clamp. The
M value (Table 2), which is an estimate of whole body
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Table 5. Intermediate-density lipoprotein (IDL) apolipoprotein B (apoB100) (Sf 12–20) and low-density lipoprotein (LDL) apoB100 (Sf 0 to 12)
metabolism in patients and control subjects
IDL ASR IDL ASR IDL Transfer Direct Total LDL LDL ASR LDL Total IDL
apoB100 apoB100 apoB100 to LDL catabolism FCR apoB100 apoB100 FCR
mg mg/day mg/kg/day pools/day pools/day pools/day mg mg/day pools/day
ESRD patients (N = 6)
1 146 183 2 3.3 0.8 4.1 611 136 1.0
2 522 31 0 2.3 0.0 2.3 1367 3 0.9
3 592 35 0 1.9 0.1 2.0 1733 7 0.6
4 157 12 0 3.5 3.5 7.0 731 27 0.8
5 440 31 0 1.4 0.6 2.0 1221 66 0.5
6 223 156 2 5.1 0.0 5.1 1351 129 0.9
Mean ± SEM 347 ± 80NS 74 ± 30NS 1 ± 0NS 2.9 ± 0.5NS 0.8 ± 0.6NS 3.7 ± 0.8NS 1169 ± 173NS 61 ± 24 0.8 ± 0.1NS
Peritonal dialysis patients (N = 5)
7 268 61 1 2.1 0.0 2.1 845 22 0.7
8 302 67 1 1.9 0.0 1.9 1008 63 0.6
9 348 44 1 3.1 0.0 3.1 842 31 1.3
10 364 13 0 1.2 0.7 1.9 680 9 0.6
11 267 48 1 3.4 0.0 3.4 491 27 1.9
Mean ± SEM 310 ± 20NS 46 ± 10NS 1 ± 0NS 2.3 ± 0.4NS 0.1 ± 0.1NS 2.4 ± 0.3NS 773 ± 88NS 30 ± 9a 1.0 ± 0.3NS
Control subjects (N = 7)
Mean ± SEM 194 ± 12 61 ± 29 1 ± 0 3.8 ± 0.5 0.4 ± 0.2 4.2 ± 0.6 1239 ± 165 145 ± 31 0.7 ± 0.1
Abbreviations are: ASR, absolute synthesis rate; NS, not significant; FCR, fractional catabolic rate.
aP < 0.05, compared to controls.
Table 6. De novo lipogenesis (DNL), total cholesterol synthesis, and palmitate fluxes in patients and control subjects
Ra palmitate, Ra palmitate,
DNL DNL FSR basal insulin %
VLDL-1 % VLDL-2 % cholesterol %/day lmol/kg/min lmol/kg/min reduction
ESRD patients (N = 6)
1 1.6 1.1 2.0 2.3 1.4 41
2 2.2 0.9 0.7 2.2 1.7 20
3 1.9 7.0 0.6 3.1 1.2 58
4 3.9 3.1 1.3 3.0 1.7 42
5 0.2 2.9 1.3 - - -
6 1.9 4.8 1.2 3.4 2.1 37
Mean ± SEM 2.0 ± 0.5NS 3.3 ± 0.9NS 1.2 ± 0.2NS 2.8 ± 0.2NS 1.6 ± 0.2NS 39 ± 6NS
Peritoneal dialysis patients (N = 5)
7 2.2 1.3 1.7 2.2 1.3 43
8 1.5 1.1 2.4 2.6 2.2 14
9 3.3 0.2 1.5 3.9 2.4 38
10 3.1 2.9 0.9 3.4 1.3 61
11 0.8 0.2 1.0 1.6 1.0 36
Mean ± SEM 2.2 ± 0.5NS 3.0 ± 0.9NS 1.5 ± 0.3NS 2.7 ± 0.4NS 1.6 ± 0.3NS 38 ± 8NS
Control subjects (N = 7)
Mean ± SEM 1.5 ± 0.6 1.6 ± 0.9 1.5 ± 0.2 2.7 ± 0.4 1.0 ± 0.2 59 ± 7
Abbreviations are: ESRD, end-stage renal disease; VLDL, very low-density lipoprotein; Ra, rate of appearance; NS, not significant; FSR, fractional synthesis rate.
insulin sensitivity, was not different between the groups.
Insulin sensitivity (Table 2) tended to be lower in both pa-
tient groups compared to controls (P = 0.08 by ANOVA).
Similar conclusions were drawn, when the data were ex-
pressed per BSA (data not shown).
DNL and fractional cholesterol synthesis
DNL, the hepatic production of fatty acids using glu-
cose as substrate, is measured as 13C-palmitate enrich-
ment in VLDL-1 and VLDL-2. Data are shown in Table 6.
No significant difference was found for DNL measured in
VLDL-1 and VLDL-2 fraction in patients and controls.
No significant difference was found for fractional
cholesterol synthesis in patients and control subjects
(Table 6).
Lipolysis
Mean plasma palmitate enrichment of all subjects mea-
sured at plateau during basal conditions was 1.73% ±
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0.17% (range 0.67% to 2.91%) and 3.18% ± 0.28%
(range 1.06% to 5.88%) at the end of the insulin infusion.
The rate of appearance of palmitate is shown in Table 6.
Under basal conditions Ra palmitate was not different
among the three groups. During the euglycemic hyper-
insulinemic clamp, Ra palmitate tended to be higher in
ESRD and peritoneal dialysis subjects compared to con-
trols (P = 0.08 by ANOVA). Palmitate release was 20%
higher in ESRD and peritoneal dialysis patients com-
pared to controls.
Correlations
Considering the data in controls and patients together,
several parameters were tested. VLDL-1 apoB100 pool
size and VLDL-2 apoB100 pool size as well as IDL
apoB100 pool size correlated only with its correspond-
ing total FCR (VLDL-1, r2 = 0.381, P < 0.01; VLDL-2,
r2 = 0.755, P < 0.0001; IDL, r2 = 0.47, P < 0.01) and
not with its synthesis rate. This observation is confirmed,
when the patient group (N = 11) was tested separately
(VLDL-1, r2 = 0.376, P = 0.02; VLDL-2, r2 = 0.746, P
< 0.01; IDL, r2 = 0.492, P < 0.05). VLDL-1 apoB100
ASR correlated with Ra palmitate during insulin infusion
(r2 = 0.404, P = 0.01).
No association was observed for VLDL-1 apoB100
FCR, VLDL-2 apoB100 FCR, transfer to VLDL-2 and
transfer to IDL with M value or insulin sensitivity index.
Furthermore, no association was observed for VLDL-
1 apoB100 secretion either expressed as mg/day or
mg/kg/day with insulin sensitivity index, or plasma insulin
in patients and controls.
DISCUSSION
There is still debate about the mechanisms explain-
ing altered VLDL apoB100 kinetics in chronic renal fail-
ure, since an impaired triglyceride removal or apoB100
clearance alone [11, 12] or reduced clearance in combina-
tion with increased triglyceride synthesis rate or VLDL
apoB100 overproduction [13, 14] have been reported.
Our data support the concept that both overproduction
of VLDL-1 apoB100 as well as decreased clearance of
VLDL-1 apoB100 and VLDL-2 apoB100 is involved.
Previous studies have measured only total VLDL
metabolism. However, evidence is present that VLDL-1
apoB100 and VLDL-2 apoB100 are independently reg-
ulated [42], which may not be reflected by total VLDL
kinetics. In the present study, the combination of VLDL-
1 apoB100 and VLDL-2 apoB100 secretion rates was not
different between patients and controls (P = 0.17, by
ANOVA), explaining the discrepancy in literature con-
cerning VLDL apoB100 overproduction.
Increased VLDL production can be secondary to the
observed insulin resistance since we showed that insulin
sensitivity tended to be lower in patients with ESRD and
peritoneal dialysis patients compared to controls (P =
0.08 by ANOVA) (Table 2) as also reported by other
groups [17, 18]. As peritoneal dialysis is initiated, insulin
sensitivity remains similar, since no differences in mean
M value or insulin sensitivity index between the ESRD
and peritoneal dialysis group is observed. A reduction in
peripheral insulin sensitivity has been postulated to lead
to increased free fatty acid availability from muscle and
adipose tissue that could, by increased substrate delivery
to the liver, stimulate VLDL-1 apoB100 release [43, 44].
In agreement with this hypothesis, we found impaired
suppression of free fatty acids by insulin in ESRD and
peritoneal dialysis patients (Table 6). In addition, VLDL-
1 apoB100 production was strongly associated with free
fatty acid release (Ra palmitate) during insulin infusion
(r2 = 0.404, P = 0.01). While VLDL-1 apoB100 release
tended to be higher in ESRD patients, it clearly reached
significance in the patients that were on peritoneal
dialysis.
As free fatty acid fluxes were similar for peritoneal dial-
ysis and ESRD patients while VLDL apoB100 release
was higher in peritoneal dialysis, the contribution of dif-
ferent sources of substrate for VLDL apoB100 release in
peritoneal dialysis patients such as DNL, or altered free
fatty acid oxidation should be taken into account [19]. We
measured the contribution of DNL to VLDL-triglyceride
availability. From our data it is clear, that DNL prob-
ably does not contribute to increased VLDL-triglyceride
availability, since no significant differences were found
for patients and control subjects (Table 6). DNL is below
5% in both patients groups, data that are in agreement to
what is reported for healthy controls [35]. This suggests no
direct effect of glucose absorption via the peritoneum on
VLDL-triglyceride availability in peritoneal dialysis pa-
tients, although an indirect effect cannot be excluded. In
peritoneal dialysis, free fatty acid oxidation has been re-
ported to be normal or reduced depending on the amount
of glucose absorbed via the peritoneum [45, 46]. Taken
together, increased free fatty acids per se or increased
free fatty acid flux in combination with altered free fatty
acid oxidation contributes to increased VLDL-1 apoB100
release in peritoneal dialysis.
In addition to increased VLDL-1 apoB100 secretion,
defects in VLDL-1 apoB100 and VLDL-2 apoB100
catabolism are observed in peritoneal dialysis compared
to ESRD. Correlation studies showed that VLDL-1
apoB100 and VLDL-2 apoB100 pool sizes were asso-
ciated with its corresponding total FCR, but not with
its ASR. VLDL-2 apoB100 ASR tended to be lower in
peritoneal dialysis patients, despite an increased VLDL-
2 apoB100 pool size. This suggests that catabolism is
more predominant for VLDL-1 apoB100 and VLDL-2
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apoB100 pool size than synthesis. One can speculate
about the disturbances for catabolism like lipoprotein li-
pase (LPL) or apoprotein loss.
LPL is an insulin-sensitive enzyme, which is a mediator
for hydrolysis of triglycerides. Therefore, it is tempting to
speculate that LPL expression and activity could be dis-
turbed in chronic renal failure. Unfortunately, no clear
consensus can be drawn for LPL activity, since LPL ac-
tivity is reported to be normal or reduced in chronic renal
failure [6, 47]. In the subjects studied, no association was
observed for VLDL-1 apoB100 FCR, VLDL-2 apoB100
FCR, transfer to VLDL-2 and IDL with indexes of in-
sulin sensitivity (M value and insulin sensitivity index).
In addition, hemodialysis patients have a lipid pheno-
type that is much milder compared to peritoneal dialysis,
while LPL is similar [6], suggesting that LPL per se is
putatively not a limiting factor for VLDL catabolism. In
the nephrotic syndrome, a decreased clearance of VLDL
apoB100 has also been reported [24], while Deighan et al
[48] showed that VLDL-1 particles deficient in apoCII,
apoCIII, and apoE are circulating in this condition. Such
an observation was also found more recently by Moberly
et al [49] for peritoneal dialysis subjects. Since in vitro
evidence suggests that apoCII, apoCIII, and apoE are
important for binding and clearance of lipoprotein parti-
cles, it is tempting to speculate that (apo)protein loss in
dialysis fluid may have contributed to defective clearance
of VLDL particles in peritoneal dialysis.
Alternatively, protein loss could also be a stimulus for
increased (lipo)protein synthesis. It has been suggested
that urinary albumin loss in nephrotic syndrome results
in enhanced hepatic (lipo)protein synthesis [24, 28]. In
ESRD and peritoneal dialysis, protein loss in urine and
dialysis fluid is considerable [22, 50, 51], ranging from 5 to
15 g/day. In order to cope this loss, the human body has
to adapt to this response by alterations in synthesis or
catabolism of the lost protein. Recently, we have shown
that albumin and fibrinogen are coordinately upregulated
in ESRD and peritoneal dialysis [51]. Therefore, it is
tempting to speculate that secretion rates of other liver
derived proteins like VLDL-1 apoB100 might be close
related to albumin ASR. However, no close correlation
was observed between albumin or fibrinogen synthesis
rate and VLDL-1 apoB100 synthesis rate, nor total pro-
tein loss and VLDL-1 apoB100 synthesis rate in patients
with chronic renal failure and control subjects, suggesting
that the occurence of a coordinated upregulation is not
likely present for VLDL-1 apoB100.
In this study, no significant differences were found for
IDL apoB100 kinetics in ESRD and peritoneal dialysis
patients, although IDL apoB100 pool size tended to be
higher for both patient groups. In other reports, where
more subjects were included, IDL apoB100 pool size was
significantly higher in ESRD and peritoneal dialysis pa-
tients compared to control subjects [6, 49].
No significant difference was observed for LDL
apoB100 pool size between patients and controls, which is
in accordance with most other studies [6, 52], although an
increased LDL apoB100 pool size also has been reported
[49]. LDL apoB100 synthesis rate was significantly lower
in peritoneal dialysis patients as also observed by Ho¨rkko¨
et al [52].
The current data are primarily focused om VLDL.
Overproduction of VLDL particles in combination with
reduced clearance of VLDL particles will inevitably re-
sult in the formation of small dense LDL, the atherogenic
particle that may contribute to progression of atheroscle-
rosis. Despite disturbances in cholesterol composition
among the different lipoprotein fractions in peritoneal
dialysis [7, 8, 49], the FSR of cholesterol for both pa-
tient groups and controls was within the normal range
(Table 6). Care is needed in interpretation of these data,
however, as total FSR of cholesterol reflects cholesterol
synthesis in all tissues and not only cholesterol circulating
in plasma.
Our study does have some limitations. It is important to
note that apoB100 metabolism was studied during fasting
condition. In the postprandial state, increased concentra-
tions of triglyceride-rich particles (chylomicrons) lead to
an increase in the release of free fatty acids and genera-
tion of remnants as a result of lipolysis by LPL. Extrapo-
lation of the reported data to the daily situation suggests
that VLDL-1 apoB100 synthesis might even be higher. In
addition, during both studies, peritoneal dialysis subjects
performed no dialysis. We choose this approach, since
glucose absorption might affect apoB100 synthesis, via
the action of insulin [42].
CONCLUSION
VLDL-1 apoB100 pool in peritoneal dialysis patients
is enlarged due increased VLDL-1 apoB100 release in
combination with reduced VLDL-1 apoB100 catabolism,
while VLDL-2 apoB100 pool results from a decreased
catabolism. Such mechanisms are already present in the
predialysis state and are aggravated significantly as peri-
toneal dialysis treatment is initiated. Our data suggest
that insulin resistance and associated enhanced free fatty
acid delivery to the liver may contribute to the lipid ab-
normalities in ESRD and peritoneal dialysis. In addition,
there appear to be specific peritoneal dialysis–related ab-
normalities in VLDL catabolism as well. As the resulting
prolonged circulation of VLDL-1 particles results in the
formation of small dense LDL, the most atherogenic par-
ticle, these abnormalities constitute an important thera-
peutic target in these patients. In particular, the recent
introduction of new thiazolidinediones (TZDs), which
improve insulin sensitivity may be of interest in this
respect.
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